896 results about "Gastric juices" patented technology

A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.

The invention relates to enterococcus faecium for feeding as well as a freeze-drying fungicide and applications thereof, and discloses enterococcus faecium LAB12 CGMCC (China General Microbiological Culture Collection Center) No.4847 which is grampositive cocci, has no spores, grows well on an MRS agar plate, forms a round bacterial colony with the diameter of 0.5-1mm within 48 hours and is used for feeding, and the bacterial colony is round, smooth and upheaved, and is a shape of grey white dewdrop; the enterococcus faecium grows in a facultative anaerobic condition; the growth temperature range is 10 DEG C-45 DEG C; the optimum growth temperature is 30 DEG C-40 DEG C; and the growth pH value is 4-10, and the optimum pH value is 6.0. The freeze-drying fungicide formed by the bacterial strain is nontoxic and harmless, is gastric juice resistant, is cholate resistant, has a high inhibitory effect for multiple harmful bacteria, has a long quality guarantee period, can be widely applied to birds and livestock breeding to strengthen the animal disease-resistant capability, and is expected to be the substitution of antibiotics for feeding.

A pellet contains a pharmaceutically active substance embedded in a polymer matrix of one or more water-insoluble polymers; wherein said polymer matrix comprises 10 to 90% by weight of an anionic polymer; with the proviso that the pellet a) releases no more than 10% of said active compound in a release test according to USP in artificial gastric juice at pH 1.2 after 120 min, and b) releases at least 50% of the active compound after altogether a further 300 min at pH 6.8 and/or pH 7.5; wherein said pellet has a particle size in the range from 300 to 1100 μm.

The invention discloses a lactobacillus plantarum and a preparation method thereof for high-density culture and freeze-drying bacteria powder, and has the technical scheme that the lactobacillus plantarum (Lactobacillus plantarum P8) is probiotics separated from the traditional fermentation milk product (yoghurt) of the Urat Middle Banner of Inner Mongolia Bayan Nur. The probiotics has the characteristics of artificial gastric juice and artificial digestive juice tolerance, cholate tolerance, intestinal agglutination action and common pathogenic entero bacteria inhibition. The bacterial strain of the bacteria is collected in the China general microbiological culture collection center with the collection number of CGMCC (China general microbiological culture collection center) No. 5468 on 18th, Nov., 2011.

A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide fast onset of baclofen or R-baclofen activity with prolonged absorption and minimal undesirable side effects.

The invention belongs to the field of biomedical engineering materials, and discloses a loaded chitosan (CS)/sodium alginate (SALG) double-crosslinking hydrogel with a colon target and a preparation method and an application thereof. In the invention, the hydrogel is firstly crosslinked with chitosan and then with sodium alginate, the medicine is wrapped in the chitosan, the sodium alginate is coated on the outer layer, and then double crosslinking is performed by the calcium ion and glutaraldehyde, the carboxy and amine are both fixed to form an interpenetrated network, and such a structure is not easy to be degraded and not easy to lose in the body fluid of human beings. After medicine loading, a small amount of medicine can be released after two hours in the gastric juice, and nearly no medicine is released after 4 hours in the intestine, while more medicine is released in the colon, and long-time release can be realized, which makes up the medicine burst release, medicine leakage and easy degradation and loose of materials reflected by the loaded gel prepared in the above, and colon targeting positioning and long-time release of medicine for treatment can be realized.

The invention discloses a quality control method of metformin hydrochloride enteric coated tablet, comprising the aspects of character, identification, examination and content measurement; wherein, release examination comprises the release quantity examination of acid in hydrochloric acid solution of 0.1 mol/l and the release quantity examination in phosphate buffer with the pH value of 6.8; the examination of relevant substances comprises the following steps: dicyandiamide is taken as reference, sulfonic group cation exchange bonded silica is taken as filler, ammonium dihydrogen phosphate solution of 1.7 percent with the pH value of 3 is mobile phase and the high performance liquid chromatography is used for examining the relevant substances. The invention controls the release quantity of the metformin hydrochloride enteric coated tablet in gastric juice strictly, reduces the adverse reaction of patients effectively, improves the release quantity of the metformin hydrochloride enteric coated tablet in the buffer solution (simulated intestinal juice) and ensures the dissolution of the enteric coated tablet in the intestinal juice effectively; the invention also adds the examination of dicyandiamide impurity under the examination item and enhances the safety of the medicine.

An active compound-containing pellet has a polymer coating of an anionic (meth)acrylate copolymer and a pharmaceutically active substance, embedded in a polymer matrix of one or more polymers, a particle size in the range from 300 to 1100 μm, a friability of at most 0.1%, measured using 200 g of pellets in a screening machine having a 200 μm screen, a screening diameter of 20 cm and 1.5 mm shaking amplitude at a shaking frequency of 50 l/sec for 10 min in the presence of six rubber cubes having a 1.8 cm edge length, with the proviso that the pellet releases no more than 10% of the active compound in a release test according to USP in artificial gastric juice at pH 1.2 after 120 min.

The present invention discloses a drug sustained and controlled release microparticle preparation for treating intestinal diseases. The preparation comprises: a pill core containing the drug, wherein the pill core contains 5-aminosalicylic acid and an assistant material; an isolation layer for providing a smooth and flat surface for the microparticle and preventing the drug from penetrating into a sustained release coating layer, wherein the penetration of the drug into the sustained release coating layer can affect the release effect, the used material of the isolation layer comprises one or a plurality of materials selected from a water-soluble polymer and an anti-adhesion agent; the sustained release coating layer for slowly releasing the drug, wherein different drug release levels can be achieved through adjusting the thickness of the sustained release coating layer, the used material of the sustained release coating layer mainly adopts a sustained-release material; an enteric-coating layer, the enteric-coating layer is provided for avoiding the early release of the drug in gastric juice, reducing stimulation of the main drug to stomach, increasing the local concentration of the drug in the lesion location, the used material of the enteric-coating layer mainly adopts a polymer enteric material. The invention further discloses a preparation method for the microparticle preparation. According to the present invention, the drug and the sustained release coating material are uniformly dispersed on the surface of the pellet, such that the problem of mixing uniformity of the assistant material and the main drug can be effectively solved.

The invention relates to an enteric plant hollow capsule which is prepared by a method comprising: firstly adding 60-85% of pectin, 5-20% of plasticizer, 5-10% of coagulant aid and 5-10% of water used for curing agent into a reaction pot; stirring and dissolving at 60-90 DEG C, and obtaining glue stock by filtering and adjusting specific gravity; removing air bubbles and then sending into a capsule production line for the treatment such as dipping in glue, drying, cooling, demoulding, cutting, sheathing, etc. The enteric plant hollow capsule has the disintegration time limit of 3-4h in gastric juice and 30-45min in intestinal juice. Compared with the existing enteric capsule, the enteric plant hollow capsule omits the working procedure of coating, simplifies the technique, and completely uses no organic solvent, thus not only being beneficial to safe production and environmental protection, but also being beneficial to improving the efficiency and reducing the cost.

The invention relates to a gastric-juice-soluble film-coating premix and the preparation method. The components include film-forming material (principal film-forming material and non-principal film-forming material), plasticizer, antisticking agent, surfactant and unorganic colorant. The preparation method of the gastric-juice-soluble film-coat premix is that: principle film-forming material is put into a super-mixer whose temperature is between 20 to 80 DEG C to mix at a low speed for 5minutes,and then after the plasticizer and the surfactant being added, to mix at a high speed for 20 minutes to get dispersive medium; then the dispersive medium, the lubricant and the unorganic colorant are added into the super-mixer to be dispersed at a high speed for 30 minutes; then the non-principal film-forming material and the plasticizer are added to mix at a low speed for 5 minutes; the finished product can be got after being screened. The gastric-juice-soluble film-coat premix which adopts complete hydrosolvent system is of moderate viscosity, so that good suspending state can be maintained; relatively low permeability can ensure the stability of the preparation; with improved production efficiency, improved moistureproof effect of the traditional Chinese medicine, more delicate coat and brighter color, the invention can better meet the requirements of the solid medicine for the film-coating.

A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.

The invention discloses a Pickering emulsion as well as a preparation method thereof. The Pickering emulsion comprises the following components in percentage by weight: 0.05-3% of starch nanocrystals, 0.001-2% of amino acids, 10-90% of edible oil and the balance of water. The prepared Pickering emulsion remains stable in a wide acidic range with the pH of 1-5; under an alkaline condition, the demulsification time of the emulsion can be controlled by adjusting the type of starch nanocrystals and amino acids which are compounded and used as well as the concentration and proportion of starch nanocrystals and amino acids; meanwhile, in a process of simulating human digestion, the Pickering emulsion disclosed by the invention achieves the slow-release effect of being stable in gastric juice and being released in intestinal juice. Therefore, the Pickering emulsion disclosed by the invention can be used as a safe and effective controlled release system for stomach and intestine for conveying active components in foods, health products or drugs, and has a relatively good application prospect.

The invention discloses an Enterococcus faecalis strain SBD, of which the collection number is CGMCC No.4848. The strain is a Gram positive strain and is spherical according to observation with microscope, and the strain does not form spores; the strain can well grow on a Mann, Rogosa and Sharpe (MRS) agar plate and can grow into a round, smooth and raised bacterial colony like a grey white dew and with a diameter of 0.5 to 1 millimeter within 48 hours; and the strain can grow in a facultatively anaerobic environment, the growth temperature range is from 10 to 50 DEG C, the optimal growth temperature is 30 to 40 DEG C, and the growth pH value range is from 4 to 10 and the optimal pH value is 6.5. The bacterial preparation made by the strain is nontoxic and safe, can resist gastric juice and cholate, has a strong inhibition effect on various harmful bacteria and can be widely used in livestock breeding industry (by directly adding into daily ration or drinking water of animals) to increase the disease resistance in animals; and the preparation is expected to replace antibiotic for feed purpose and can obviously improve average weight of weaned piglets, reduce a feed-to-meat ratio and improve living environment of livestock and therefore has a bright prospect.

The invention discloses lactobacillus plantarum CQ02-108 and application thereof to preparation of fermented sausages. The lactobacillus plantarum CQ02-108 is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 17, 2018; and the preservation number is CGMCC No. 16121. The lactobacillus plantarum CQ02-108 can be used for producing proteinase and rapidly producing acid, does not cause viscosity, produce gas, produce biological amine, produce H2O2, produce H2S and produce pigments, and also has the advantages of high-salt concentration tolerance, high acidity tolerance, inhibition of growth of escherichia coli and staphylococcus aureus, bile salt resistance and gastric juice tolerance. When the lactobacillus plantarum CQ02-108 is used for fermenting the sausages, the quantity of viable bacteria of lactic acid bacteria in the fermented sausages can be remarkably improved and the pH (Potential of Hydrogen) value of the sausages is reduced; and the growth ofharmful bacteria is inhibited and the quality of the fermented sausages can be remarkably improved.

The invention provides bacillus subtilis (Bacillussubtilis) shou003, an anti-vibrio protein and a preparation method and applications of the bacillus subtilis shou003 and the anti-vibrio protein. The preparation method of the anti-vibrio protein comprises the following steps: screening out bacillus subtilis shou003 (preserved in China Center for Type Culture Collection with a number of CCTCC No.: M2013571 on November 13, 2013) from intestinal tract of a healthy large yellow croaker; and then extracting the anti-vibrio protein from the fermentation broth of bacillus subtilis shou003, wherein the amino acid sequence of the anti-vibrio protein is shown as SEQ ID No.: 1. The bacillus subtilis shou003 and the anti-vibrio protein show good effects on inhibiting aquatic pathogenic bacteria, in particular pathogenic vibrio; in addition, the bacillus subtilis shou003 shows outstanding tolerance to temperature, NaCl, gastric juice, intestinal juice and cholate and can be widely applied to the prevention of germs during aquaculture; on that basis, the optimal fermentation culture method of the bacillus subtilis shou003, and a preparation method of the anti-vibrio protein are provided.

A patient stomach fullness sensor is employed in conjunction with an optional patient angle sensor to shut off or to reverse the flow of fluid in a gastric tube when the combination of stomach fullness and patient angle relative to the horizontal becomes sufficient to indicate that gastric juices may enter the esophagus or go even higher. In this way incidents of aspirational pneumonia in hospitalized patients is significantly reduced or eliminated.

The invention provides an engineering strain of recombinant expression lipase. Lipase gene obtained by cloning in Aspergillus niger is transferred into Trichoderma reesei, so that Trichoderma reesei engineering strain can be constructed and has the preservation number of China Center for Type Culture Collection (CCTCC) No.: M2012483. The recombinant expression lipase has the optimal action pH of 5.0 and the optimal action temperature of 30 DEG C, and the tolerance of the recombinant expression lipase to gastric juice, pepsase and artificial intestinal juice can be enhanced. The lipase remarkably improves the utilization rate of oil matter in feed, thus remarkably reducing the addition of oil in the feed and reducing the cost of the feed.